Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET-ECMO trial
jRCT1041240069Recruiting
- Start
- Oct 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in cardiogenic shock, myocardial infarction (MI), Cardiomyopathies and 1 more (2 arms). Primary endpoint: Hierarchical composite outcome within 7 days. Started Oct 2024; status: recruiting.
02
Drugs
heparin
03
Conditions
cardiogenic shockmyocardial infarction (MI)Cardiomyopathiesmyocarditis
Beyond the preview
Go deeper on jRCT1041240069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240069.